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ABSTRACT
Post-Translational Modifications of Satellite Cells During the Repair of Injured Skeletal Muscle
Justin E. Sperringer, B.S.

Satellite cells are normally a quiescent skeletal muscle stem cell pool that upon activation
rapidly proliferate and differentiate to repair damaged muscle fibers. The paired box transcription
factor 7 (Pax7) is the canonical biomarker for quiescent, activated, and proliferating satellite cells and
is rapidly down-regulated upon differentiation into myofibers. However, the factors that regulate the
modulation of Pax7 are largely unknown. Post-translational modifications to Pax7 provide a viable
means to activate or deactivate this transcription factor through the signaling cascade of skeletal muscle
repair and regeneration. The sirtuin 1 (Sirt1) protein, a histone deacetylase, has been shown to be
involved in many cellular processes, including the differentiation of myoblasts. Although Sirt1 is noted
for its role in the differentiation of myoblasts, it is not known if it directly interacts with Pax7. The
general control of amino acid synthesis protein 5-like 2 (GCN5), an acetyltransferase, is known to work
in conjunction with Sirt1 modulating PGC-1α in hepatic gluconeogenesis. With this information, it is
logical to test if GCN5 also works with Sirt1 in the satellite cell response to muscle injury. The primary
objective of this study is to determine the role of GCN5 and Sirt1 on Pax7-mediated regulation of
satellite cell function. We tested the novel hypothesis that GCN5 is a binding partner with Pax7 and
acts on Pax7 via acetylation leading to satellite cell activation and proliferation while Sirt1 is another
binding partner of Pax7 and acts on Pax7 via deacetylation. The tibialis anterior (TA) muscles of wildtype mice were injected with cardiotoxin (CTX) to induce muscle injury. The TA muscles where
harvested 4, 7, 14, or 21 days post-injection to analyze the satellite cell response to regulate muscle
repair following the CTX injury. Western Blot data showed that the total protein abundance of Pax7,
GCN5, and acetylated protein at 57kD (Pax7 molecular weight) were significantly up-regulated 4, 7,
and 14 days post CTX injection, but had returned to basal levels by 21 days post CTX injection. From
4 through 14 days post injection Pax7 abundance was ~592%, 204%, and 219% greater compared to
control muscles. GCN5 abundance was ~215%, 330%, and 213% greater from 4 through 14 days post
injection, and acetylated protein at 57kD was ~651%, 291%, and 404% greater compared to controls.
The abundance of Sirt1 protein was significantly increased at 14 days post CTX injection with ~ 259%
greater abundance compared to control muscles and approached basal levels by 21 days post CTX
injection. Although not significant, there was ~111% greater abundance of Sirt1 protein 7 days post
CTX injection relative to control muscles. Immunoprecipitation studies showed that GCN5 was
directly associated with Pax7 during all recovery time points, with 21 days post CTX injury not having
as strong association compared to the other time points. The membrane was then stripped and probed
for acetylated lysine, which mirrored the GCN5 association pattern. Sirt1 was also tested for interaction
and showed to be directly interacting with Pax7 during the 7, 14, and 21 days post CTX injury time
points. Immunohistochemistry confirmed that Pax7 and GCN5 were co-localized to muscle nuclei in
the 4 day regenerating muscles; this confirms that Pax7 and GCN5 interact during activation and
proliferation of satellite cells. Immunohistochemistry also confirmed that Pax7 and Sirt1 were colocalized in the 14 day regenerating muscles; this confirms that Pax7 and Sirt1 interact during the
differentiation of myoblasts. These novel data support the hypotheses that GCN5 acetylates Pax7 to
rapidly activate and proliferate satellite cells in response to skeletal muscle damage while Sirt1
deacetylates Pax7 to differentiate myoblasts.
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Chapter 1 – Specific Aims & Hypotheses
Skeletal muscle damage is a common problem for people of all ages, fitness levels, and the
ability of muscle regeneration in response to injury is suppressed in aging and in a variety of metabolic
and muscle wasting diseases. Skeletal muscle regeneration is a highly orchestrated process that requires
the activation and differentiation of skeletal muscle stem cells, known as satellite cells. While normally
quiescent, the self-renewing proliferation of these cells not only maintains the satellite cell population,
but also provides numerous myogenic-committed cells that proliferate, differentiate, fuse, and lead to
new myofiber formation and repair the contractile properties of the myofibers1–4.
The exact process mediating the activation and proliferation of satellite cells is currently not
known due to the complex nature of the signaling cascade. However, it is possible that the regulation of
satellite cells involves paired box transcription factor 7 (Pax7), because Pax7 is highly expressed in
both quiescent and activated satellite cells. Nevertheless, the mechanisms controlling Pax7 function in
satellite cells is largely unknown. Our preliminary studies have identified two proteins that may be
important for regulating satellite cell function in response to injury repair. Specifically, our preliminary
data indicated that the general control of amino acid synthesis protein 5-like 2 (GCN5), physically
bound with and activated Pax7 by an acetylation-dependent mechanism in activated satellite cells.
However, it was not known if the class III histone deacetylase Sirtuin 1 (Sirt1) physically bound with
and deactivated Pax7 during myogenesis in response to muscle repair.
The primary objective of this novel study was to determine the role of GCN5 and Sirt1 on
Pax7-mediated regulation of satellite cell function during muscle repair. It was hypothesized that GCN5
is a binding partner of Pax7 and acts on Pax7 via acetylation, leading to satellite cell activation,
proliferation, and self-renewal. We also evaluated a second hypothesis that Sirt1 is a binding partner of
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Pax7 and acts on Pax7 via deacetylation, leading to myoblast differentiation. Our rationale for this
project is that a delineation of the potential importance of GCN5 and Sirt1 on satellite cell function
would potentially provide opportunities for improving muscle repair following injury with persons with
metabolic disease and aging, who tend to have reduced rates of injury repair.
The central hypothesis will be addressed by the following two aims:
Specific Aim #1:
Determine if GCN5 is a binding partner of Pax7 and acts on Pax7 via acetylation.
The hypothesis for Specific Aim #1 is that GCN5 is a binding partner of Pax7, and will transfer acetyl
groups to Pax7.
Specific Aim #2:
Determine if Sirt1 is a binding partner of Pax7 and acts on Pax7 via deacetylation.
The hypothesis for Specific Aim #2 is that Sirt1 is a binding partner of Pax7, and will remove acetyl
groups on Pax7 via deacetylation.
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Chapter 2 – Background & Significance
Satellite Cells
Satellite cells are a normally quiescent stem cell population within skeletal muscle. They have
acquired their name from their anatomical location, which is between the basal lamina and the
sarcolemma of myofibers1. Quiescent satellite cells are mitotically inactive and remain in G0 phase
until activation1,2. The functional aspect of quiescence relates to their anatomical morphology, with
these cells having a large nuclear to cytoplasmic ratio, few organelles, a small nucleus, and condensed
interphase chromatin4. During myogenesis, satellite cells have the ability to undergo symmetric or
asymmetric division, with asymmetric division allowing the cell to maintain the satellite cell pool by
contributing a new quiescent cell to the pool1–3. While the exact signaling for activated satellite cells is
unknown, the nucleus expresses certain proteins that indicate what stage they are undergoing.
Using 3H thymidine tracing experiments, Snow et. al.6 showed that satellite cells are mitotically
quiescent in adult skeletal muscle, but quickly enter the cell cycle following muscular injury6.
Commitment to the cell cycle demonstrates that satellite cells will produce proliferating myoblasts that
are essential to muscular regeneration1. Satellite cells are capable of both symmetric and asymmetric
cellular division1,2. Symmetric cell division is where the satellite cell divides into two identical
daughter cells with the same cellular fate while asymmetric cell division produces one quiescent
daughter cell and a progenitor cell (myoblast)3. Understanding the nuclear expression of certain
proteins indicates what stage they are undergoing.
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Above image from Yin et. al.1

In work published by Schultz et. al., the morphologic structure of satellite cells goes hand in
hand with the fact that these cells are mitotically quiescent and transcriptionally inactive in healthy,
unstressed muscle1,7. Identification of these cells during their progress through quiescence to activation
is important for tracking them and understanding their function. Pax7 is the canonical biomarker for
quiescent and activated satellite cell, but becomes deactivated upon entering the differentiation stage4.
Other proteins, such as Myf5 and MyoD, begin to increase their levels during differentiation when the
activated satellite cells have committed to differentiate into myoblasts1,4. The protein myogenin is
another biomarker that is expressed in differentiating myoblasts, leading to complete commitment to a
myogenic lineage1.
Pax7 is frequently used as the major indicator for satellite cells in the quiescent or proliferative
stage. All quiescent, activated, and proliferating satellite cells highly express Pax7, but the level of
Pax7 dramatically decreases in differentiating myoblasts and myotubes while other factors, such as
MyoD, Myf5, and myogenin become highly expressed4. Schultz found that the majority of satellite
cells readily enter the cell cycle (~80% - termed the “responsive population”) while the remainder does
so in a much slower manner (termed the “reserve population”)4. He proposed that the reserve
population undergoes symmetric division, maintaining the satellite cell pool4. However, this reserve
4

population can and will undergo asymmetric division to enter the proliferative state if extensive muscle
growth or regeneration is needed4.
After activation, the myogenic-committed satellite cells express both Myf5 and MyoD3. The
importance of Pax7 is further demonstrated in the satellite cell signaling cascade based on its
interactions with Myf5. Pax7 activates Myf5 expression by recruiting histone methyltransferase
complex (HMT) and histone H3 lysine 4 (H3K4) at the promoter of the Myf53,8. Pax7+/Myf5+ cells upregulate the expression of MyoD, triggering the proliferation of the satellite cells8,9. Another key
component that works in concert with Pax7 is FoxO3, which binds to the promoter region of Pax7 to
recruit RNA polymerases10. The presence of MyoD+/Pax7- cells indicates differentiating satellite cells
that will contribute to new or regenerating myotubes1,3.

Above picture from Yin et. al.1
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GCN5
Histones are proteins found in eukaryote nuclei that are bound to DNA for packaging, and order
the DNA into structures known as nucleosomes. Nucleosomes are the basic units of chromatin
composed of DNA wrapped around histone octomers11. Nucleosomes consist of approximately 146
base pairs of DNA and two copies each of histones H2A, H2B, H3, and H411. Histone
acetyltransferases (HATs) modify the histones by transferring acetyl groups from acetyl coenzyme A
(Acetyl CoA) to the lysine residues11. GCN5 is a HAT that primarily targets lysine K14 on H3 as well
as lysine K8 and lysine K16 on H411,12. Because Pax7 is a nuclear transcription factor that is upregulated during the activation and proliferation of satellite cells, post-translational modification of
Pax7 may be necessary to activate its transcriptional function. One of the common pathways to activate
transcription factors is the modification of their acetylation states (acetylation or deacetylation), which
can activate Pax7 to initiate transcriptional function. With this information, GCN5 may be a potential
acetyltransferase to activate the satellite cell transcription factor Pax7 by acetylation.
The first metazoan HAT observed was p55. It was also shown to be homologous to yeast
GCN513. From there, a whole host of HATs emerged and were subsequently divided into five families:
the GCN5-related N-acetyltransferases (GNATs), the MOZ, Ybf2/Sas3, Sas2, and Tip60 (MYST)
related HATs, the p300/CREB binding protein/associated factor (CBP/PCAF) HATs, the general
transcription factor HATs (TAF1), and the nuclear hormone-related HATs (SRC1 and
ACTR/SRC3)11,14,15. Of particular concern for this proposal, vertebrates have two genes encoding for
GCN5-like factors, the GNATs and PCAF11,16. PCAF stands for p300/CBP associated factor and is 73%
identical to GCN516.
There are two domains within the GCN5 structure, the C-terminal domain and the N-terminal
domain. The N-terminal domain is very similar to the PCAF and actually contains a sub-domain named
the PCAF homology domain. The C-terminal domain contains two sub-domains: the AT domain and
6

the bromodomain. It is the AT domain that is responsible for transferring the Acetyl CoA to proteins17–
19

. The bromodomain in GCN5 and PCAF also function as an acetylase11. With the work done by Zeng

and Zhou in 2002, it was demonstrated that the bromodomain recognizes the acetylated lysine on
histones to play a role in chromatin remodeling and transcription activation20. Owen et al. were able to
show that the bromodomain of GCN5 binds to the acetylated lysine K16 on histone H421. However, the
PCAF bromodomain was shown to bind to the acetylated lysine K8 on histone H4 tail and the
acetylated lysine K14 on histone H322. In both the GCN5 and PCAF bromodomains, the authors
provide evidence to show that the bromodomains contribute to the histone acetylation by bridging the
acetylation to specific chromosomal transcription sites11,20,21. Histone acetylation is a post-translational
modification that influences the activity of the histones23. Histones that are hypoacetylated are
transcriptionally repressed while the hyperacetylated histones are transcriptionally active23.
While both of these acetyltransferases play an important role, GCN5 is an essential protein for
development in animals11. In work done by Xu et al., GCN5-/- mice expire during embryogenesis
because they fail to form the dorsal mesoderm24. These animals expired approximately 10.5 days post
coitum24. The combination GCN5-/- and PCAF -/- mice show a sooner expiration time with deaths
occurring between 7.5 and 9.5 days post coitum24. However, in PCAF -/- mice, GCN5 is drastically
increased as a compensatory mechanism and produce viable offspring24,25. This indicates that GCN5 is
necessary for proper development through its HAT activity and will compensate for PCAF HAT
abnormalities.
An important but unanswered question is how GCN5 is activated to acetylate histones. In work
published by Dominy, Jr. et. al., the deacetylase Sirt6 was shown to activate GCN55. The work looked
at how the acetylation and deacetylation of PGC-1α affected hepatic gluconeogenesis. Activation of
PGC-1α stimulates hepatic gluconeogenesis by increasing the expression of enzymes necessary for the
generation of new glucose5. Acetylation of PGC-1α has been shown to repress its activity by relocating
7

PGC-1α away from promotor regions of the target genes. GCN5 is known to acetylate PGC-1α,
resulting in its repression not only in the liver, but also in skeletal muscles5,26–28.

With this information pertaining to GCN5's ability to acetylate histones in the nucleus, it is very
possible that GCN5 acts as the initial activator for the activation of Pax7 in the nucleus. Because
quiescent and proliferating satellite cells express Pax7, the post-translational modifications to Pax7 are
key in understanding the activation process of the satellite cells. However, the activation and
differentiation of these myogenic stem cells is necessary for the muscle to regenerate. As stated
previously, the differentiation of myoblasts accompanies a complete dissolution of Pax7 expression and
a marked increase in Myf5, MyoD, and MyoG expression levels. The preliminary data suggests that
GCN5 is the activator of Pax7 by acetylation, it is logical that a deacetylase is responsible for the
deactivation of Pax7 allowing differentiation to continue.
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Sirt1

Sirtuins are silent information regulators of the nicotinamide adenine dinucleotide-dependent
deacetylases in the histone family29,30. There are currently seven members of this family, all of which
consist of a central catalytic domain, but differ at the C and N-terminal domains29. One major
difference between the sirtuins and other classes of histone deacetylases is that all sirtuins require
NAD+ for their enzymatic activity29,31,32. Sirt1 is a focus of this study and is found primarily (although
not exclusively) in the nucleus29. Sirt1 is known to act as a catalyst in the transfer of acetyl groups from
the target protein to the NAD+, leading to the formation of NAM and deacetylate the target27,29,31–35.
Due to the requirement of NAD+, Sirt1 is considered an energy sensor that is increased in
response to increased NAD+ availability29. This is attributed to the NAD+/NADH ratio, which drives
the mitochondrial production of ATP through the NADH dehydrogenase complex29. The NAD+/NADH
ratio has also been found to be increased when nutrients are limited and when energy expenditure is
increased, which are also conditions where Sirt1 activation has been observed29,30,32. Another level of
NAD+ regulation that relates directly to Sirt1 activity is the NAD+ salvage pathway, where NAM is
converted to NMN (NAM mononucleotide) by the NAM phosphoribosyltransferase (Nampt) and
converted back to NAD+ by NMN adenylyltransferase29–32. The key to this pathway is Nampt, which
has been found to be the rate-limiting step and increases Sirt1 activity29,31,33.
With this information, it can be shown that any condition increasing the NAD+/NADH ratio by
increasing the production of NAD+ will lead to elevated Sirt1 activity31. The converse of this is also
true where decreasing the NAD+/NADH ratio or competitive consumers of NAD+ can lead to inhibition
of Sirt1 activity31. One of these competitive NAD+ consumers that indirectly inhibits Sirt1 activity is
the poly-ADP ribose polymerase 1 (PARP-1)28,29,31. In studies conducted by Bai et al., it was
demonstrated that there is an increase in Sirt1 deacetylase activity through inhibition of PARP-136,37.
9

The proposed primary roles of Sirt1 are to promote mitochondrial biogenesis and increase gene
transcription in skeletal muscle29. Sirt1 has been shown to target a number of different histones and
other proteins, with three major targets: the peroxisome proliferator-activated receptor γ-coactivator 1α (PGC1-α), myogenic determination factor (MyoD), and the forkhead box transcription factors O1 and
3a (FoxO1 & Fox3a)27–30,34,36–39.
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Sirt1 Targets
PGC1-α plays key roles in mitochondrial biogenesis and fatty acid oxidation in the skeletal
muscle. Activated Sirt1, via sensing decreased nutrient availability and/or an increased NAD+/NADH
ratio, deacetylates PGC1-α at the promoter region of genes involved in mitochondrial biogenesis and
fatty acid oxidation, resulting in increased transcription of PGC1-α-dependent genes28,31,37. Another
suggested possible target for Sirt1 deacetylation is the metabolic sensor AMP activated protein kinase
(AMPK), which also increases mitochondrial biogenesis and fatty acid oxidation31. It has also been
shown that AMPK can regulate Sirt1 activity indirectly by increasing the NAD+/NADH ratio31. This
would suggest a positive feedback system between Sirt1 and AMPK31.
Sirt1 also has been demonstrated to complex with the histone acetyltransferases p300/CBP
associated factor. These transferases impose control over amino acid synthesis in muscle and are
known to be the master regulator of the satellite cell differentiation factor MyoD29,38. During periods of
increased NAD+, Sirt1 maintains MyoD in the deacetylated state, therefore inhibiting MyoD’s
transcription38. This illustrates the negative regulation of Sirt1 on MyoD, resulting in inhibition of the
differentiation process of myoblasts38.
In a follow-up study by Fulco et al., it was noted that myoblast differentiation (via MyoD) was
impaired during glucose restriction and was dependent on the AMPK-Nampt-Sirt1 pathway33. The
authors concluded that this pathway acts as a checkpoint for differentiation of satellite cells to prevent
the energy demanding differentiation process due to low nutrient availability33. However, Canto et al.
have proposed that the interaction of Sirt1 and AMPK is much more complex than previously thought.
They demonstrated that the inhibition of Nampt did not inhibit the NAD+/NADH ratio or PGC1-α
acetylation31.
Over-expression of Sirt1 has been shown to promote proliferation of satellite cells29,38.
Rathbone et al. suggest that the enhanced proliferative capacity of satellite cells in Sirt1 over11

expression is likely due to the inhibition of cyclin D/CDK4 inhibitor p2138. Specifically, Sirt1 decreases
p21Waf/Cip1 protein which inhibits cyclin D-cdk4/6 activity, which progresses the cell cycle38. This data
implies that Sirt1 regulates the cell cycle progression in early G1 through S phases38.
The family of Sirt proteins are known deacetylases, with Sirt1 being the primary antagonist of
GCN5 in the PGC-1α pathway, since both act upon PGC-1 . With this information, Dominy, Jr. et. al.
tested several Sirts and found that Sirt6 actually dramatically increased the acetylation of PGC-1α, the
complete opposite of what was thought would happen5. Co-immunopricipitations of FLAG Sirt6 from
nuclear fractions of U-2 OS found endogenous GCN5 bound to Sirt65. The converse was also found
true with FLAG GCN5 being bound to Sirt6. This showed a clear interaction of the two proteins5.
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Chapter 3 – Methods and Procedures Summary
Study Design Overview

Short term and long term studies will be conducted to observe the different stages of satellite
cells during activation, proliferation, and differentiation. For the short term group, the mice (n = 12)
will be injected in the right and left tibialis anterior (TA) with 1x cardiotoxin (CTX) and 1x phosphate
buffered saline (PBS), respectively, with the right being the experimental leg and the left being the
control leg. The animals will then be sacrificed 4 days post injection to observe activation and
proliferation of satellite cells. Muscle tissues will then be subject to a battery of experimental
procedures outlined below to determine Pax7, GCN5, and Sirt interactions. The long term group of
mice will be separated into 3 groups (each group, n = 4) to observe satellite cell differentiation and
muscle regeneration. The mice will be subject to the same experimental procedures to induce muscle
damage, but will be sacrificed at 7, 14, and 21 days post injection to observe varying degrees of muscle
repair and regeneration. These muscle tissues with varying degrees of repair and regeneration will then
be subject to the same battery of experimental procedures to observe Pax7, GCN5, and Sirt
interactions. As described in the specific aims and hypotheses, the short term and long term design will
allow for the observation of these proteins during different stages of satellite cell activation,
proliferation, and differentiation.

Mouse Model

C57BL/6, Sirt1wt/flox mice between 3 to 6 months of age were obtained from Jackson Labs. All
mice were conditional wild-types. Mice were anesthetized with 2-4% isoflurane and allowed to rest 10
minutes prior to experimental procedures. The tibialis anterior (TA) muscle of one limb was injected
13

with 70µL (1mg · mL-1 in distilled H2O) of cardiotoxin (CTX) from naja mossambic mossambic
obtained from Sigma-Aldrich. Seventy microliters of 1x phosphate buffered saline (PBS) was injected
along the length of the contralateral TA muscle. The animals were examined 4, 7, 14, or 21 days after
CTX or PBS injection. The animals were housed at 20°C in barrier-controlled conditions under a 12:12
hour light-dark cycle. Proper animal care standards were followed by adhering to the recommendations
for the care of laboratory animals as advocated by the American Association for Accreditation of
Laboratory Animal Care and by following the policies and procedures detailed in the Guide for the
Care and Use of Laboratory Animals as published by the United States Department of Health and
Human Services and proclaimed in the Animal Welfare Act (PL89-544, PL91-979, and PL94-279). All
experimental procedures carried approval by the Institutional Animal Care and Use Committee from
West Virginia University.

Surgical Procedures

The mice were anesthetized with 2-4% isoflurane and this was maintained throughout the
terminal surgeries. Once the TA muscles were harvested, the mice were euthanized by myocardial
excision.

Western Blot Analysis

Whole muscle samples were extracted using RIPA lysis buffer to enable protein extraction from
the cytoplasm, membrane, and nuclear proteins. Coomassie (Bradford) protein assay was conducted to
acquire the protein concentrations for loading samples prior to gel electrophoresis. Protein lysate of
12.5μg was separated by protein electrophoresis using 4-12% Bis-Tris (NuPage, Invitrogen CA) gels at
200 volts. The proteins were transferred to a nitrocellulose membrane (Protran BA 85, Whatman GE
14

Healthcare Life Sciences) at 4°C for 2:20 hours at 170mA in transfer buffer. The membranes were then
cut for specific proteins and blocked in 2% Advanced Enhanced Chemiluminescence (ECL) blocking
reagent (GE Healthcare UK Limited) for 1 hour prior to incubating overnight with gentle rocking at
4°C in the appropriate antibodies. The following day, the membranes were washed in Tris buffered
saline with 0.1% Tween-20 (TBST) then incubated in the appropriate horse radish peroxidase
conjugated secondary antibody for 1 hour. The membranes were washed in TBST, incubated in ECL
according to the manufacturer’s instructions, and imaged using G:BOX (Syngene).

Immunoprecipitation

To reduce non-specific binding, 175µg · µL-1 of protein was pre-cleaned with 25µL of protein
A/G beads (Invitrogen) for 1 hour with rotation at 4°C. Beads were separated from protein using a
magnetic separator (Dynal Bead Separator, Invitrogen). The Pax7 antibody (Santa Cruz) and lysate
were co-incubated for 2 hours at 4°C. The antigen and antibody solution was added to new pre-cleaned
A/G beads and incubated overnight at 4°C. Beads were then separated using a magnetic separator and
washed three times in a washing buffer before electrophoresis. Protein in the resulting lysate was
separated by routine Western Blot methods that have been established in our laboratory 40,41,43.

Immunohistochemistry

Frozen muscle sections (7μm) were obtained with a Leica CM3050 S cryostat and placed on
FisherBrand Superfrost Plus glass slides. The tissue sections fixed in 4% paraformaldehyde and
permeabilized in 0.4% Triton X at 4°C. The slides were then blocked hour in normal goat serum and
incubated with a Pax7-FITC tagged antibody (Developmental Studies Hybridoma Bank) at 1:50
dilution overnight at 4°C. The following morning, the slides were washed in PBS then incubated in
15

diluted horse serum for blocking followed by overnight incubation at 4°C in either GCN5 or Sirt1.
After incubating the slides in appropriate secondary antibody, the slides were then washed and covered
with 4`, 6-diamidino-2-phenylindole (DAPI) to visualized the nuclei in the tissue section (ProLong
Gold Antifade Reagent with DAPI, Invitrogen). An Olympus MVX10 MacroView microscope
equipped with an Hamamatsu ORCA_Flash 4.0v2 sCMOS camera was used for fluorescent imaging
using EXFO X-Cite 120 fluorescence illumination system. Max zoom of 25.2x magnification was used
to acquire images. The software used was CellSens 1.9 Dimension Acquisition Software.

Statistical Analysis

All blot quantifications were obtained using GelQuant.NET version 1.8.2
(BiochemLabSolutions.com). Quantified values were then normalized to appropriate controls and
analyzed using GraphPad Prism 6 (GraphPad Software, Inc.). Statistical significance values were
obtained by a 2-way ANOVA.
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Post-Translational Modifications of Satellite Cells During the
Repair and Regeneration of Injured Skeletal Muscle

Justin E. Sperringer1,3, Junaith S. Mohamed1,3, & Stephen E. Alway1,2,3
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University School of Medicine, 2West Virginia Center for Clinical and Translational Science Institute,
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Abstract

Satellite cells are normally a quiescent skeletal muscle stem cell pool that upon activation
rapidly proliferate and differentiate to repair damaged muscle fibers. The paired box transcription
factor 7 (Pax7) is the canonical biomarker for quiescent, activated, and proliferating satellite cells and
is rapidly down-regulated upon differentiation into myofibers. However, the factors that regulate the
modulation of Pax7 are largely unknown. Post-translational modifications to Pax7 provide a viable
means to activate or deactivate this transcription factor through the signaling cascade of skeletal muscle
repair and regeneration. The sirtuin 1 (Sirt1) protein, a histone deacetylase, has been shown to be
involved in many cellular processes, including the differentiation of myoblasts. Although Sirt1 is noted
for its role in the differentiation of myoblasts, it is not known if it directly interacts with Pax7. The
general control of amino acid synthesis protein 5-like 2 (GCN5), an acetyltransferase, is known to work
in conjunction with Sirt1 modulating PGC-1α in hepatic gluconeogenesis. With this information, it is
logical to test if GCN5 also works with Sirt1 in the satellite cell response to muscle injury. The primary
objective of this study is to determine the role of GCN5 and Sirt1 on Pax7-mediated regulation of
satellite cell function. We tested the novel hypothesis that GCN5 is a binding partner of Pax7 and acts
on Pax7 via acetylation leading to satellite cell activation and proliferation while Sirt1 is another
binding partner of Pax7 and acts on Pax7 via deacetylation. The tibialis anterior (TA) muscles of wildtype mice were injected with cardiotoxin (CTX) to induce muscle injury. The TA muscles where
harvested 4, 7, 14, or 21 days post-injection to analyze the satellite cell response to regulate muscle
repair following the CTX injury. Western Blot data showed that the total protein abundance of Pax7,
GCN5, and acetylated protein at 57kD (Pax7 molecular weight) were significantly up-regulated 4, 7,
and 14 days post CTX injection, but had returned to basal levels by 21 days post CTX injection. From
4 through 14 days post injection Pax7 abundance was ~592%, 204%, and 219% greater compared to
control muscles. GCN5 abundance was ~215%, 330%, and 213% greater from 4 through 14 days post
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injection, and acetylated protein at 57kD was ~651%, 291%, and 404% greater compared to controls.
The abundance of Sirt1 protein was significantly increased at 14 days post CTX injection with ~ 259%
greater abundance compared to control muscles and approached basal levels by 21 days post CTX
injection. Although not significant, there was ~111% greater abundance of Sirt1 protein 7 days post
CTX injection relative to control muscles. Immunoprecipitation studies showed that GCN5 was
directly associated with Pax7 during all recovery time points, with 21 days post CTX injury not having
as strong association compared to the other time points. The membrane was then stripped and probed
for acetylated lysine, which mirrored the GCN5 association pattern. Sirt1 was also shown to be directly
interacting with Pax7 during the 7, 14, and 21 days post CTX injury time points.
Immunohistochemistry confirmed that Pax7 and GCN5 were co-localized to muscle nuclei in the 4 day
regenerating muscles; this confirms that Pax7 and GCN5 interact during activation and proliferation of
satellite cells. Immunohistochemistry also confirmed that Pax7 and Sirt1 were co-localized in the 14
day regenerating muscles; this confirms that Pax7 and Sirt1 interact during the differentiation of
myoblasts. These novel data support the hypotheses that GCN5 acetylates Pax7 to rapidly activate and
proliferate satellite cells in response to skeletal muscle damage while Sirt1 deacetylates Pax7 to
differentiate myoblasts.
Key Words: Pax7, GCN5, Sirtuin 1, Muscle Repair, Satellite Cells
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Introduction
Skeletal muscle damage is a common problem for people of all ages, fitness levels, and the
ability of muscle regeneration in response to injury is suppressed in aging and in a variety of metabolic
and muscle wasting diseases. Skeletal muscle regeneration is a highly orchestrated process that requires
the activation and differentiation of skeletal muscle stem cells, known as satellite cells. While normally
quiescent, the self-renewing proliferation of these cells not only maintains the satellite cell population,
but also provides numerous myogenic-committed cells that proliferate, differentiate, fuse, and lead to
new myofiber formation and repair the contractile properties of the myofibers1–4.
The exact process mediating the activation and proliferation of satellite cells is currently not
known due to the complex nature of the signaling cascade. However, it is possible that the regulation of
satellite cells involves paired box transcription factor 7 (Pax7), because Pax7 is highly expressed in
both quiescent and activated satellite cells. Nevertheless, the mechanisms controlling Pax7 function in
satellite cells is largely unknown. Our preliminary studies have identified two proteins that may be
important for regulating satellite cell function in response to injury repair. Specifically, our preliminary
data indicated that the general control of amino acid synthesis protein 5-like 2 (GCN5), physically
bound with and activated Pax7 by an acetylation-dependent mechanism in activated satellite cells.
However, it was not known if the class III histone deacetylase Sirtuin 1 (Sirt1) physically bound with
and deactivated Pax7 during myogenesis in response to muscle repair.
The primary objective of this novel study was to determine the role of GCN5 and Sirt1 on
Pax7-mediated regulation of satellite cell function during muscle repair. It was hypothesized that GCN5
is a binding partner of Pax7 and acts on Pax7 via acetylation, leading to satellite cell activation,
proliferation, and self-renewal. We also evaluated a second hypothesis that Sirt1 is a binding partner of
Pax7 and acts on Pax7 via deacetylation, leading to satellite cell differentiation. Our rationale for this
project is that a delineation of the potential importance of GCN5 and Sirt1 on satellite cell function
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would potentially provide opportunities for improving muscle repair following injury with persons with
metabolic disease and aging, who tend to have reduced rates of injury repair.

Methods

Mouse Model
C57BL/6, Sirt1wt/flox mice between 3 to 6 months of age were obtained from Jackson Labs. All
mice were conditional wild-types. Mice were anesthetized with 2-4% isoflurane and allowed to rest 10
minutes prior to experimental procedures. The tibialis anterior (TA) muscle of one limb was injected
with 70µL (1mg · mL-1 in distilled H2O) of cardiotoxin (CTX) from naja mossambic mossambic
obtained from Sigma-Aldrich. Seventy microliters of 1x phosphate buffered saline (PBS) was injected
along the length of the contralateral TA muscle. The animals were examined 4, 7, 14, or 21 days after
CTX or PBS injection. The animals were housed at 20°C in barrier-controlled conditions under a 12:12
hour light-dark cycle. Proper animal care standards were followed by adhering to the recommendations
for the care of laboratory animals as advocated by the American Association for Accreditation of
Laboratory Animal Care and by following the policies and procedures detailed in the Guide for the
Care and Use of Laboratory Animals as published by the United States Department of Health and
Human Services and proclaimed in the Animal Welfare Act (PL89-544, PL91-979, and PL94-279). All
experimental procedures carried approval by the Institutional Animal Care and Use Committee from
West Virginia University.

Surgical Procedures
The mice were anesthetized with 2-4% isoflurane and this was maintained throughout the
terminal surgeries. Once the TA muscles were harvested, the mice were euthanized by myocardial
excision.
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Western Blot Analysis
Whole muscle samples were extracted using a RIPA lysis buffer. Coomassie (Bradford) protein
assay was conducted to acquire the protein concentrations for loading samples prior to gel
electrophoresis. Protein lysate of 12.5μg was separated by protein electrophoresis using 4-12% Bis-Tris
(NuPage, Invitrogen CA) gels at 200 volts. The proteins were transferred to a nitrocellulose membrane
(Protran BA 85, Whatman GE Healthcare Life Sciences) at 4°C for 2:20 hours at 170mA in transfer
buffer. The membranes were then cut for specific proteins and blocked in 2% Advanced Enhanced
Chemiluminescence (ECL) blocking reagent (GE Healthcare UK Limited) for 1 hour prior to
incubating overnight with gentle rocking at 4°C in the appropriate antibodies. The following day, the
membranes were washed in Tris buffered saline with 0.1% Tween-20 (TBST) then incubated in the
appropriate horse radish peroxidase conjugated secondary antibody for 1 hour. The membranes were
washed in TBST, incubated in ECL according to the manufacturer’s instructions, and imaged using
G:BOX (Syngene).

Immunoprecipitation
To reduce non-specific binding, 175µg · µL-1 of protein was pre-cleaned with 25µL of protein
A/G beads (Invitrogen) for 1 hour with rotation at 4°C. Beads were separated from protein using a
magnetic separator (Dynal Bead Separator, Invitrogen). The Pax7 antibody (Santa Cruz) and lysate
were co-incubated for 2 hours at 4°C. The antigen and antibody solution was added to new pre-cleaned
A/G beads and incubated overnight at 4°C. Beads were then separated using a magnetic separator and
washed three times in washing buffer before electrophoresis. Protein in the resulting lysate were
separated by routine Western Blot methods that have been established in our laboratory 40,41,43.
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Immunohistochemistry
Frozen muscle sections (7μm) were obtained with a Leica CM3050 S cryostat and placed on
FisherBrand Superfrost Plus glass slides. The tissue sections fixed in 4% paraformaldehyde and
permeabilized in 0.4% Triton X at 4°C. The slides were then blocked hour in normal goat serum and
incubated with a Pax7-FITC tagged antibody (Developmental Studies Hybridoma Bank) at 1:50
dilution overnight at 4°C. The following morning, the slides were washed in PBS then incubated in
diluted horse serum followed by overnight incubation at 4°C in either GCN5 or Sirt1. After incubating
the slides in appropriate secondary antibody, the slides were then washed and covered with 4`, 6diamidino-2-phenylindole (DAPI) to visualized the nuclei in the tissue section (ProLong Gold Antifade
Reagent with DAPI, Invitrogen). An Olympus MVX10 MacroView microscope equipped with an
Hamamatsu ORCA_Flash 4.0v2 sCMOS camera was used for fluorescent imaging using EXFO X-Cite
120 fluorescence illumination system. Max zoom of 25.2x magnification was used to acquire images.
The software used was CellSens 1.9 Dimension Acquisition Software.

Statistical Analysis
All blot quantifications were obtained using GelQuant.NET version 1.8.2
(BiochemLabSolutions.com). Quantified values were then normalized to appropriate controls and
analyzed using GraphPad Prism 6 (GraphPad Software, Inc.). Statistical significance values were
obtained by a 2-way ANOVA.
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Results
Determine if GCN5 is necessary for Pax7 acetylation
It was hypothesized that GCN5 is a binding partner of Pax7 and acts on Pax7 via acetylation,
leading to satellite cells activation and proliferation. Before the direct interaction of Pax7 and GCN5
could be assessed, the presence of GCN5 in CTX injured muscles needed to be confirmed. Western
Blot analysis was performed for all recovery periods to determine expression of the proteins of interest
(Appendix Figures 1-5).
Pax7 is the canonical biomarker for satellite cells and its expression is dramatically upregulated upon muscle injury1-4. Using Western Blot analysis to determine protein content from 4-21
days post injection, we were able to illustrate Pax7 expression through the various stages of muscle
regeneration (Figure 1). Four days post injection of CTX into the TA indicates the early injury phase
and should correspond to significant activation of satellite cells, resulting in dramatic up-regulation of
Pax7+ cells. As demonstrated in Figure 1, 4 days of recovery after CTX injury resulted in significant
up-regulation of Pax7 (p = 0.003). This corresponded to a 592.2% greater Pax7 protein content in
experimental CTX injected muscles compared to control PBS injected muscles. By 7 days post CTX
injection, some of the myoblasts should have begun differentiating to regenerate the damaged muscle
but the majority of myoblasts will continue to proliferate and provide sufficient nuclei for the
regeneration process. The data show that Pax7 abundance is significantly up-regulated by 204.1% as
compared to the control muscle (p = 0.006) 7 days post CTX injury (Figure 1). By 14 days post CTX
injection, it would be expected to see a leveling off of Pax7 protein expression, as the differentiation of
myoblasts should be more prominent for the repair process. However, Pax7 protein abundance
remained elevated by 219.1% as compared to the control muscle (p<0.001) after 14 days of recovery.
CTX injected muscle has regained the muscle weight and even gained mass (hypertrophied) and Pax7
protein abundance had returned to basal levels after 21 days of recovery (Appendix Table 1).
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Figure 1: Pax7 Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown 4,
7, 14, and 21 days after the respective
injections. B.) The relative expression of
Pax7 data from the Western Blots are
summarized in the histograms for the
control and experimental muscles at each
time point. Pax7 was normalized to
GAPDH. Pax7 expression was significantly
up-regulated in the 4, 7, and 14 day recovery
periods. By 21 days post CTX injection,
Pax7 levels returned to basal control muscle
levels.* control vs. experimental = p < 0.05.

Figure 1: Pax7 Protein Abundance

While it is known that Pax7 is expressed in quiescent, activated, and proliferating satellite cells,
the modifications to Pax7 itself are largely unknown in the satellite cell signaling cascade. Our
preliminary data suggested that the acetyltransferase GCN5 associated with Pax7 during the satellite
cell response to muscle injury. To follow-up these observations GCN5 was studied using Western Blots.
We found that 4, 7, and 14 days post CTX injury, GCN5 protein content was significantly up-regulated
in the experimental muscle compared to the control muscles (Figure 2). GCN5 protein content was
found to be significantly greater (p < 0.0001) in 4, 7, and 14 day recovery muscles (Figure 2). This
resulted in 215.5%, 330.4%, and 212.9% greater amount of protein compared to control muscles,
respectively. These data would be consistent with the idea that GNC5 is an important regulator of
satellite cell proliferation (e.g., at day 4), but is trending to return to basal levels during maturation and
differentiation of the myoblasts (e.g., days 14 and 21).
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Figure 2: GCN5 Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX, and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown
for4, 7, 14, and 21 days after the respective
injections. B.) The relative expression of
GCN5 data from the Western Blots are
summarized in the histograms for the
control and experimental muscles at each
time point. GCN5 was normalized to
GAPDH. GCN5 expression was
significantly up-regulated in the 4, 7, and
14 day recovery periods. By 21 days post
CTX injection, GCN5 levels returned to
basal control muscle levels. ** control vs.
experimental = p < 0.01.

Figure 2: GCN5 Protein Abundance
Since GCN5 is an acetyltransferase that is hypothesized to be acting on Pax7 in the satellite cell
mediated repair and regeneration of injured muscle, it was necessary to test for acetylated protein in the
Western Blot data. The Pax7 blot was stripped and probed with an acetylated lysine to test for
acetylated protein. Although we recognize that the Western Blot is not-specific for Pax7, and the probe
for acetylation will only show total acetylated protein in the Pax7 range of 57kD we have interpreted
the change in acetylated protein at 57kD to be indicative of Pax7 acetylation. Our data show that
acetylation at 57kD (i.e., Pax7) was elevated during the early points of satellite cell proliferation (e.g.,
days 4-14) but declined during the period when differentiation of myoblasts rather than proliferation
would be the dominant signal (Figure 3). Acetylated protein at the 57kD range was found to be
significantly up-regulated (p < 0.0001) across the 4, 7, and 14 day recovery time points (Figure 3). This
resulted in 650.7%, 291.2%, and 403.7% greater amount of protein compared to control muscles,
respectively (p < 0.05).
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Figure 3: Acetylated Protein @ 57kD
Abundance
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX, and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown 4,
7, 14, and 21 days after the respective
injections. B.) The relative expression of
acetylated protein at 57kD data from the
Western Blots are summarized in the
histograms for the control and experimental
muscles at each time point. Acetylated
protein at 57kD was normalized to
GAPDH. Acetylated protein @ 57kD
expression was significantly up-regulated
in the 4, 7, and 14 day recovery periods. By
21 days post CTX injection, Pax7 levels
returned to basal control muscle levels. *
control vs. experimental = p < 0.05.

Figure 3: Acetylated Protein @ 57kD Abundance

Immunoprecipitation protocols directly show the interaction between proteins. The Pax7 protein
from tissue lysates was pulled-down with a Pax7 antibody and probed to determine binding partners for
this protein (Appendix Figures 6-9). GCN5 was probed for and found to be directly associated with
Pax7 at all time points (Figure 4). The interaction was most prominent in the 4 and 7 day recovery
periods (Figure 4). This clearly demonstrates that GCN5 and Pax7 are directly bound to each other
during the satellite cell mediated repair and regeneration of skeletal muscle.
Figure 4: Pax7-GCN5 Interaction.
Representative Western Blot images from the
Pax7 pull-down and probed for GCN5 are
shown for experimental (Ex.) injured muscles
that were injected with CTX, and the
contralateral control (Ctrl.) muscles that were
injected with PBS. Blots are shown 4, 7, 14,
and 21 days after the respective injections

Figure 4: Pax7-GCN5 Interaction
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Blotting the Pax7 pull-down with the acetylated lysine antibody was used to determine the
extent of Pax7 acetylation. The data show that Pax7 was acetylated, clearly showing an interaction
between the acetylated lysine and the Pax7, indicating that Pax7 is acetylated. As with the IP data
probed with GCN5, the acetylation of Pax7 was most prominent in the 4 and 7 day recovery muscles
(Figure 5).
Figure 5: Pax7 Acetylation.
Representative Western Blot
images from the Pax7 pulldown probed for acetylation
are shown for experimental
(Ex.) injured muscles that were
injected with CTX, and the
contralateral control (Ctrl.)
muscles that were injected with
PBS. Blots are shown 4, 7, 14,
and 21 days after the respective
injections.

Figure 5: Pax7 Acetylation
To confirm that GCN5 is the acetyltransferase that is directly interacting with Pax7 in the
satellite cell mediated repair and regeneration of muscle, immunohistochemical (IHC) co-localization
of Pax7 and GCN5 was performed on the 4 day recovery muscles (Figure 6). There was significant
damage to the muscles, illustrating the effectiveness of CTX to induce muscle injury. The data confirms
that GCN5 co-localizes with the Pax7+ nuclei, further confirming the direct interaction of Pax7 and
GCN5 in the satellite cell response to muscle injury.
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Figure 6: Pax7-GCN5 Co-localization.
Representative immunohistochemical images from co-localization of Pax7 and
GCN5 4 days post CTX injection. Top left is the nuclear stain (DAPI), top right is
the Pax7 stain (FITC), bottom left is the GCN5 stain (Cy3), and bottom left is the
merge of all images. Pax7 and GCN5 were found to be co-localized within each
other.
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Determine if Sirt1 is necessary for Pax7 deacetylation
The total protein abundance of Sirt1 was only significantly different between control and
experimental muscles at the 14 day recovery time point with a p = 0.00074 (Figure 7). This resulted in
a 259.4% greater protein content compared to control muscles. However, the 7 day recovery muscles
were not significant with the p = 0.0887 but had a 111.2% greater protein content compared to control
muscles.
Figure 7: Sirt1 Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured muscles
that were injected with CTX, and the
contralateral control (Ctrl.) muscle that was
injected with PBS. Blots are shown 4, 7, 14,
and 21 days after the respective injections. B.)
The relative expression of Sirt1 data from the
Western Blots are summarized in the
histograms for the control and experimental
muscles at each time point. Sirt1 was
normalized to GAPDH. Sirt1 expression was
significantly up-regulated in the 14 day
recovery period only. However, 7 days post
CTX injection had a p = 0.0887 and the CTX
injected muscle had 111.2% greater protein
content compared to the control PBS injected
muscles. ** control vs. experimental = p <
0.01.

Figure 7: Sirt1 Protein Abundance
Immunoprecipitation of Pax7 was performed on all time periods and probed for Sirt1 to
determine direct interaction between the two proteins (Figure 8). The Pax7-Sirt1 interaction was nonexistent at the 4 day recovery time point, but became prominent from 7 through 21 days post CTX
injection (Figure 8). These data clearly demonstrate that Sirt1 is directly binding to Pax7 in the satellite
cell-mediated repair and regeneration of skeletal muscle after injury.
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Figure 8: Pax7-Sirt1 Interaction.
A.) Representative Western Blot
images for the Pax7 pull-down probed
for Sirt1 are shown for experimental
(Ex.) injured muscles that were
injected with CTX, and the
contralateral control (Ctrl.) muscles
that were injected with PBS. Blots are
shown 4, 7, 14, and 21 days after the
respective injections.

Figure 8: Pax7-Sirt1 Interaction
To further confirm the interaction of Pax7 with Sirt1, immunohistochemical co-localization of a
FITC tagged Pax7with a Cy3 labeled Sirt1 was performed on the 14/21 days recovery muscles (Figure
9). There was a distinct co-localization of Pax7 and Sirt1, further confirming that Sirt1 directly binds
and interacts with Pax7 in differentiating satellite cells.
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Figure 9: Pax7-Sirt1 Co-localization.
Representative immunohistochemical images from co-localization of Pax7 and
Sirt1 14 days post CTX injection. Top left is the nuclear stain (DAPI), top right is
the Pax7 stain (FITC), bottom left is the Sirt1 stain (Cy3), and bottom left is the
merge of all images. Pax7 and Sirt1 were found to be co-localized within each
other.
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Discussion
The modulation of Pax7 through post-translational modifications in regenerating skeletal
muscle is largely unknown. In the current study we show novel data that Pax7 acetylation and the
Pax7-Sirt1 and Pax7-GCN5 bindings are altered in satellite cells during regeneration of skeletal
muscle. Data from this study supports the hypothesis that Pax7 is influenced by the acetylation status.
The data clearly support the hypothesis that in the regeneration process, the activation and proliferation
of satellite cells are mediated by the acetylation of Pax7 by the acetyltransferase GCN5. The data also
support the hypothesis that the differentiation of myogenic-committed cells is mediated by the
deacetylation of Pax7 by the deacetylase Sirt1.

GCN5 Activates Pax7 by Acetylation
Pax7 is the canonical biomarker for satellite cells and its expression is dramatically upregulated upon muscle injury1-4. Using Western Blot analysis to determine protein content from 4-21
days post injection, we were able to illustrate Pax7 expression through the various stages of muscle
regeneration (Figure 1). Four days post injection of CTX into the TA indicates the early injury phase
and should correspond to significant activation of satellite cells, resulting in dramatic up-regulation of
Pax7+ cells. As demonstrated in Figure 1, 4 days of recovery after CTX injury resulted in significant
up-regulation of Pax7 (p = 0.003). This corresponded to a 592.2% greater Pax7 protein content in
experimental CTX injected muscles compared to control PBS injected muscles. By 7 days post CTX
injection, some of the myoblasts should have begun differentiating to regenerate the damaged muscle
but the majority of activated satellite cells will continue to proliferate and provide sufficient nuclei for
the regeneration process. The data show that Pax7 abundance is significantly up-regulated by 204.1%
as compared to the control muscle (p = 0.006) 7 days post CTX injury (Figure 1). By 14 days post CTX
injection, it would be expected to see a leveling off of Pax7 protein expression, as the differentiation of
myoblasts should be more prominent for the repair process. However, Pax7 protein abundance
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remained elevated by 219.1% as compared to the control muscle (p < 0.001) after 14 days of recovery.
CTX injected muscle had regained the muscle weight and even gained mass (hypertrophied) and Pax7
protein abundance had returned to basal levels after 21 days of recovery (Appendix Table 1).
These data are consistent with numerous studies showing an increase in Pax7 abundance which
reflects the satellite cell response to muscle injury1-4. Pax7 is expressed in all quiescent and activated
satellite cells, but it is dramatically up-regulated upon muscle injury as satellite cells proliferate to
mediate repair and regeneration of the injured muscle 1-4. Once myoblasts begin to differentiate and
commit to repair the damaged muscle, Pax7 is turned off and muscle-specific transcription factors are
solely expressed, such as MyoD and myogenin1-4. This is consistent with our Western Blot data, where
4 days post CTX injection resulted in 592.2% greater Pax7 protein compared to control muscles
(Figure 1). The protein abundance of Pax7 remained significantly greater in the 7 and 14 day recovery
animals (p = 0.006 and p < 0.001, respectively) compared to controls (Figure 1). These data are
consistent with the previous studies1-4,8 and is expected during the repair and regeneration process. As
repair is in progress, there will be an initial and rapid increase in satellite cell numbers to prepare for
the repair process. Following this initial phase, some cells will begin to differentiate and contribute
nuclei to the damaged muscles while other satellite cells will continue to proliferate. This corresponds
to the 7 and 14 day recovery muscles where Pax7 was significantly lower compared to the 4 day
recovery muscles (p < 0.05); however, Pax7 was still significantly greater than the corresponding
control muscles (Figure 1). Complete repair and regeneration of damaged muscles corresponded to a
return of Pax7 to basal levels, since presumably the muscles no longer need to maintain a high level of
proliferation of satellite cells to repair damage1-4. Twenty-one days after the CTX injection, the muscles
were completely repaired and had even hypertrophied relative to the control muscles (Appendix Table
1). As expected, the corresponding Western Blots also show that Pax7 abundance had returned to basal
control levels in the repaired muscles 21 days post injury.
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While it is known that Pax7 is expressed in quiescent, activated, and proliferating satellite cells,
the modifications to Pax7 itself are largely unknown in the satellite cell signaling cascade. Our
preliminary data suggested that the acetyltransferase GCN5 associated with Pax7 during the satellite
cell response to muscle injury. To follow-up these observations, GCN5 was studied using Western
Blots. We found that 4 days post CTX injury, GCN5 protein content was significantly up-regulated (p <
0.01) in the experimental muscle compared to the control muscles but the abundance of GCN5
decreased after this time point (Figure 2). These data are consistent with the idea that GNC5 is an
important regulator of satellite cell proliferation (e.g., at day 4), but is less important during maturation
and differentiation of the activated satellite cells (e.g., days 14 and 21).
Since GCN5 is an acetyltransferase that is hypothesized to be acting on Pax7 in the satellite cell
mediated repair and regeneration of injured muscle, we decided to test for acetylated protein in the
Western Blot data. Although we recognize that the antibody to identify acetylated lysine is not-specific
for Pax7, we stripped the Pax7 membrane and re-probed it for acetylated lysine as an indicator of the
total acetylated protein in the Pax7 range of 57kD. Correspondingly, we have interpreted the change in
acetylated protein at 57kD to be indicative of Pax7 acetylation. Our data show that acetylation at 57kD
(i.e., Pax7) was elevated during the early points of satellite cell proliferation (e.g., days 4-14) but
declined during the period when differentiation rather than proliferation would be the dominant signal
(Figure 3). These observations are consistent with the hypothesis that GCN5 was active to acetylate and
activate Pax7 in the early points of repair, and this corresponded to satellite cell activation, whereas in
later periods of repair, Pax7 acetylation decreased (or deacetylation increased) to deactivate Pax7.

Pax7 is a binding partner of GCN5 during muscle repair.
Our immunoprecipitation data show that GCN5 directly interacted with Pax7 (Figure 4).
Although GCN5 was found to be associated with Pax7 at all time points (4-21 days post CTX
injection), the abundance of GCN5:Pax7 binding was not different in control and experimental legs at
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any time point. Together with the western blot data, these novel finding suggest that there is more
GCN5 protein in injured muscles (Figure 2) and that GCN5 is directly interacting with Pax7 throughout
the repair process (Figure 4). These findings provide support for the idea that GCN5 is up-regulated an
important direct activator of Pax7.
Pax7 was acetylated at all time points (Figure 5). While Pax7 acetylation was somewhat
elevated at day 4, corresponding to the period where proliferation of satellite cells would be high as
compared to later time points, additional experiments are needed to clarify if Pax7 acetylation occurs
transiently during the early periods surrounding CTX injury. Nevertheless, our immunoprecipitation
assays provide evidence to support the hypothesis that GCN5 acetylates Pax7 to activate and proliferate
satellite cells. Nevertheless, we recognize that there is some variability in GCN5:Pax7 abundance even
in control muscles. One potential explanation of this is that GCN5 is already complexed with Pax7 in
satellite cells under basal conditions. This is unlikely though because when IP data is compared to the
Western Blot data, it would be expected that Pax7 in control muscles would be less abundant in the IP.
This was not the case as the control and experimental samples in the IP yielded the same abundance.
The second possibility is that satellite cells from uninjured muscles will activate and proliferate for the
purpose of migrating to the CTX damaged contralateral limb. This is also unlikely because if this were
the case, we would expect that the Western Blot data would show an increase in Pax7 protein
abundance in the control muscles but this was not the case. A third and most likely possibility is that
there was mild physical damage and inflammation to the muscle in response to the PBS injection and
this might be compounded by a systemic “leak” of CTX from the injured muscle to the circulation,
thereby affecting the contralateral muscle. If this is true, this might be enough of a signal to increase
GCN5 without increasing Pax7 protein abundance. To test this possibility, we conducted new
experiments on cage controls animals that corresponded to 4, and 14 days of normal cage activity, PBS
only injected animals, and CTX only injected animals (Supplemental Figure 1) which suggests that
PBS may have an effect although the muscles were not injured.
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Supplementary Figure 1:
Pax7 IP Comparison
Representative Western Blot
images of the
immunoprecipitation of Pax7 at
various times and treatments
during skeletal muscle repair and
regeneration.

Supplementary Figure 1: Comparison of Pax7 Pull-Downs

Our immunohistochemical (IHC) data confirm that GCN5 co- co-localizes with the Pax7+
nuclei (Figure 6). Although we do not know if other acetyltransferases are involved in regulating Pax7,
together our data strongly support the hypothesis that the acetyltransferase GCN5 activates Pax7 by
acetylation in the satellite cell mediated repair and regeneration of injured skeletal muscle.

Sirt1 Deactivates Pax7 by Deacetylation
As our data supported a role for GCN5 acetylation to activate Pax7 in satellite cells, we then
strove to answer the next question, which protein deactivates Pax7. Logically, if Pax7 is activated by
acetylation then it should be deactivated by a deacetylase. Our laboratory has had a long standing
interest in the deacetylase Sirt1 and activators of this protein which may have several roles in skeletal
muscle regeneration and aging40-43 and we chose to examine the potential that Sirt1 could deacetylate
Pax7. As previous data showed Sirt1, a NAD+ dependent histone deacetylase, is involved in the satellite
cell mediated repair and regeneration of skeletal muscle after injury29, 30 and Sirt1 maintains MyoD in
the deacetylated state to inhibit MyoD transcription preventing differentiation of myoblasts29,38, Sirt1
was of particular interest and a strong candidate.
The initial phase of injury (4 & 7 day recovery points), the levels of Sirt1 protein, which was
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likely important to maintain MyoD in the deacetylated state to prevent myoblast differentiation, were
increased. After this initial phase, Sirt1 protein content was declined (Figure 7, 14 day recovery) that
presumably also allowed MyoD-mediated transcription for myoblast differentiation. By 21 days post
injury, Sirt1 protein levels return to the basal control levels and this would decrease the deacetylation of
Pax7 (Figure 8) as the muscle has been repaired and regenerated following CTX injury.
GCN5 was strongly associated with Pax7 in the early points of regeneration (Figure 4) and
significantly decreases with time (p < 0.001) as repair and regeneration/myoblast differentiation occurs.
In contrast, the deacetylase Sirt1 becomes more strongly associated with Pax7 (presumably to
deactivate it) as the myoblasts are differentiating. We confirmed the Pax7-Sirt1 interaction (Figure 9)
when satellite cells are primarily differentiating. This evidence along with the IP data strongly support
the hypothesis that Sirt1 directly binds and interacts with Pax7 to deacetylate and deactivate the
transcription factor during the satellite cell mediated repair and regeneration of muscle injury. Our IHC
data (Figure 9) confirm the Pax7-Sirt1 co-localization. This evidence along with the IP data strongly
support the hypothesis that Sirt1 directly binds and interacts with Pax7 to deacetylate and deactivate the
transcription factor during the satellite cell mediated repair and regeneration of muscle injury.

Conclusions
In this study we show for the first time that the post-translational modifications of Pax7 in
satellite cells in regenerating skeletal muscle involve GCN5, an acetyltransferase, which directly binds
to and acetylates Pax7 to activate and initiate proliferation of satellite cells. Although further
investigations are needed to determine the extent, necessity, or sufficiency of GCN5 in satellite cells,
the data supports the hypothesis that GCN5 is a binding partner of Pax7 and is acting on Pax7 via
acetylation, leading to satellite cell activation and proliferation. Sirt1, a histone deacetylase, was also
found to be directly acting on Pax7 in the satellite cell signaling cascade. In this novel finding, Sirt1
was directly bound to Pax7 to deacetylate and presumably deactivate Pax7. The data supports the
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hypothesis that Sirt1 is a binding partner of Pax7 and is acting on Pax7 via deacetylation, leading to
myoblast differentiation. Further experiments are needed to confirm if Sirt1 part of the deactivation
network of Pax7 in regenerating muscle.
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Chapter 5 – Findings, Limitations, & Future Research
Specific Aim #1

Specific Aim #1 was to determine if GCN5 was a binding partner of Pax7 and acts on Pax7 via
acetylation. In our research, we approached this by designing the experimental protocol to observe the
satellite cell mediated repair and regeneration of skeletal muscle from initial injury through complete
regeneration. To provide enough damage to ensure that we had enough samples, a cardiotoxin (CTX)
was injected into the tibialis anterior of mice. The mice were then allowed 4, 7, 14, or 21 days to
recover from the CTX injection and provided appropriate time points to observe the complete satellite
cell mediated repair and regeneration. Western Blot was then utilized to examine several proteins
through the repair and regeneration process. Proteins being probed for included: Pax7, Sirt1, Sirt6,
GCN5, and acetylated protein in Pax7’s molecular range of 57kD.
The 4 and 7 day Western Blots were of particular interest for the first aim, as the CTX injection
would cause a massive amount of damage and result in satellite cell activation and proliferation. As
expected, the damage to the muscles was extensive and resulted in a strong satellite cell response. This
was evident in the significant up-regulation of Pax7 protein abundance in the CTX injected muscles
compared to the control muscles in both the 4 and 7 day recovery animals. In support of the hypothesis
that GCN5 is acting on Pax7, GCN5 protein abundance was also found to be significantly up-regulated
in the 4 and 7 day recovery animals. If GCN5 is resulting in the acetylation of Pax7, it would be
expected that Pax7 is acetylated. While Western Blot analysis does not directly show interaction, it was
necessary to test for acetylation in the Pax7 molecular range of 57kD before going any further into the
investigation. We found that in the 57kD range, there was significant up-regulation of acetylated
protein in the 4 and 7 day recovery animals. With this evidence supporting the hypothesis of the first
aim, additional experimentation could be performed to further test the hypothesis.
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Immunoprecipitation (IP) of Pax7 was then conducted to show direct interaction of proteins.
Pax7 was pulled-down and probed for GCN5 to show direct interaction between the proteins. In
support of the hypothesis, we found that GCN5 was in fact directly bound to Pax7 in the 4 and 7 day
recovery mice. To provide further support that GCN5 is acetylating Pax7, the Pax7 membrane from the
IP was stripped and probed for acetylation. It was found that Pax7 was in fact acetylated in both the 4
and 7 day recovery animals. This evidence supports the hypothesis that GCN5 is acetylating Pax7 to
activate and proliferate satellite cells.
To provide further support of the hypothesis, immunohistochemical experimentation was
conducted on the 4 day recovery muscles to co-localize Pax7 and GCN5 within the nuclei of
regenerating muscle. Since Pax7 is a nuclear transcription factor that is the canonical biomarker for
activated and proliferating satellite cells, the co-localization of GCN5 would confirm the IP data that
GCN5 directly binds and acetylates Pax7 in the satellite cell mediated repair and regeneration of
skeletal muscle. It was found that GCN5 and Pax7 were co-localized within the nuclei of regenerating
muscle.
The evidence supports the hypothesis that GCN5 acetylates Pax7, resulting in the activation and
proliferation of satellite cells in the regeneration of muscle. However, there are some limitations that
prevent the absolution of the claim. The control muscle IP data is not convincing of the necessity or
sufficiency of GCN5 or acetylation as a means for the Pax7-mediated repair and regeneration of
skeletal muscle; it would be expected that the experimental blots would have significantly greater
abundance of protein compared to the control blots rather than the same abundance. One potential
explanation of this is that GCN5 is already complexed with Pax7 in satellite cells and resulting in no
real changes when an IP is performed. This is unlikely though because when IP data is compared to the
Western Blot data, it would be expected that Pax7 in control muscles would be less abundant in the IP.
This was not the case as the control and experimental samples in the IP yielded the same abundance.
The second possibility for this could be a result of the presence of activated satellite cells; it has been
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illustrated that satellite cells from uninjured muscles will activate and proliferate followed by
mobilization to a damaged area to aid in the repair and regeneration process. This is also unlikely
because the Western Blot data would show an increase in Pax7, which was not the case. A third and
most likely possibility is that there was physical damage from the needle and inflammation damage to
the muscle during the PBS injection. This would result in damage that would not necessarily be
apparent in the Western Blot, but would be during the IP due to its specificity for the pulled-down
protein. To test this possibility, we conducted new experiments on cage controls animals that
corresponded to 4, and 14 days of normal cage activity, PBS only injected animals, and CTX only
injected animals (Supplemental Figure 1) which data suggests that PBS may have an effect although
the muscles were not injured.
The second limitation of this study is that no other proteins were used for the IP. To truly
confirm GCN5 interaction of Pax7, GCN5 needs to be pulled down as well and probed for Pax7 and
acetylation. This was planned to be performed, but the -80°C freezer where the samples were stored
went out over one weekend and ruined all the samples before additional experimentation could be
performed. However, with the new experimental protocol using cage controls to determine if the PBS
control injections are truly representative of control muscles, this will allow for IP’s to be performed to
address this issue.
A third limitation in determining the necessity of GCN5 in the activation of Pax7 in satellite
cells is the lack of a transgenic mouse model. The complete ablation of GCN5 in a mouse with the
established experimental protocols would certainly shed new light and enable concrete claims. An
alternative or compliment to transgenic models would have been to isolate quiescent satellite cells from
mice and treat them with GCN5 and see if proliferation occurred. Treating with GCN5 and observing
rapid proliferation would allow for conclusions to be made. Using other acetyltransferases on the
isolated satellite cells could determine if any acetyltransferase could accomplish the activation and
proliferation and determine if GCN5 is part of the activation/deactivation process in satellite cells.
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Future work needs to be performed using both transgenic mouse models along with the isolation
and culture of satellite cells to be treated with GCN5. This will allow for definitive conclusions to be
made about the role of GCN5 in the activation and proliferation of satellite cells. Furthermore,
additional IP’s using more than just a Pax7 pull-down need to be performed.

Specific Aim #2

The second aim of this study was to determine if Sirt1 was a binding partner of Pax7 and acts
on Pax7 by deacetylation. As with the first aim, we needed to establish the abundance of Sirt1 in the
damaged muscle before attempting to show any interaction. With evidence that GCN5 is significantly
up-regulated in the early phase of satellite cell mediated repair and regeneration, the 7, 14, and 21 day
recovery muscles were of particular interest for the second aim.
In the 4 day recovery, we saw no statistical difference in Sirt1 protein abundance between the
control versus experimental muscles. By 7 days post injection, there was a dramatic increase in
abundance of Sirt1 protein, although not statistically significant. However, this resulted in 111.2%
greater protein abundance as compared to control muscles. Fourteen days post CTX injection showed
statistically significant greater protein abundance that resulted in 259.4% greater amount of protein. By
21 days post injection, Sirt1 protein levels returned to basal control levels. This illustrated to us that
Sirt1 is most prominent during the latter stage of the satellite cell mediated repair and regeneration
process. This did not show interaction of any kind with Pax7, but was necessary to see when Sirt1 was
most abundant.
With Sirt1 shown to be most prominent in the 7 and 14 day recovery muscles, we then used IP
to determine if Sirt1 is physically binding to Pax7 at any time during the repair and regeneration
process. As expected, there was almost no binding of Sirt1 to Pax7 after 4 days of recovery. By 7 days
post CTX injection, there was significant binding of Sirt1 to Pax7, which was a novel finding since it
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has not been established that Sirt1 binds to Pax7. We also found that Sirt1 was bound to Pax7 in the 14
and 21 day recovery muscles. These data support the hypothesis that Sirt1 is a binding partner of Pax7.
With the concomitant decrease in Pax7 acetylation, it is likely that Sirt1 is acting on Pax7 via
deacetylation. However, there need to be additional experimentation to test the extent of Sirt1’s
involvement with Pax7.
We next used co-localization of Sirt1 and Pax7 in the 14 day recovery muscles to further
illustrate that Sirt1 is binding to Pax7. In this experimentation, we found that Sirt1 was co-localized
with Pax7 within the regenerating muscles. This complimented the IP data by directly showing the colocalization of the two proteins in regenerating muscle. These data support the hypothesis that Sirt1 is a
binding partner of Pax7.
While these data support the hypothesis that Sirt1 is binding to Pax7 and acting upon Pax7 via
deacetylation, there were some limitations to the experimentation that prevent us from making concrete
claims about Sirt1 and Pax7’s interactions. The first limitation is the variable IP data. As with the
GCN5 experimentation, Sirt1 was found to be just as strongly associated with Pax7 in the control
muscles as it was in the experimental muscles. As stated previously, this could have been the result of
satellite cell activation in the control muscles so they can migrate and aid in the repair process or, the
more likely option, the PBS injection into the control muscles resulted in damage and inflammation
that resulted in the activation and proliferation of the control muscles. New IP data were performed
using cage controls, PBS injected only animals, and CTX injected only animals. It was found that PBS
is causing an insult of some kind resulting in a satellite cell response (Supplementary Figure 1).
The second limitation of the experimentation was a lack of an IP with Sirt1 pulled down to
confirm that Pax7 was bound to Sirt1. This would have provided a second confirmation of the Pax7
pull-down data. As previously stated, there was a -80°C freezer malfunction which resulted in the
complete loss of all the muscle samples before the Sirt1 pull-down could be performed.
A third limitation in determining Sirt1’s necessity in repair and regeneration of skeletal muscle
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is the lack of a transgenic model. As previously described, this would undoubtedly provide insight into
the necessity of Sirt1. The use of our conditional wild-type mice, being Sirt1 floxed without Cre
expression, provides a good foundation for further research. Also as stated previously, the use of
isolated satellite cells and cultured with Sirt1 and other deacetylases would determine the necessity of
Sirt1 in the differentiation process.
Future research needs to address these limitations to determine Sirt1’s necessity in the repair
and regeneration process. The use of a transgenic model and isolated satellite cells will provide the
information needed to confirm Sirt1’s interaction with Pax7 in the satellite cell mediated repair and
regeneration process.
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Appendix A: Additional Figures
Appendix Figure 1: 4 Day Recovery
Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots show Sirt1,
Pax7, Acetylation, GCN5, Sirt6, and
GAPDH proteins. B.) The relative
expression of protein data from the Western
Blots are summarized in the histograms at
the bottom of the figure for the control and
experimental muscles. The proteins are
normalized to GAPDH. Pax7, Acetylated
protein, and GCN5 were significantly upregulated compared to control muscles. *
control vs. experimental = p < 0.05 ; **
control vs. experimental = p < 0.01.

Appendix Figure 1: 4 Day Recovery Protein Abundance

Appendix Figure 2: 7 Day Recovery
Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots show Sirt1,
Pax7, Acetylation, GCN5, Sirt6, and
GAPDH proteins. B.) The relative
expression of protein data from the Western
Blots are summarized in the histograms at
the bottom of the figure for the control and
experimental muscles. The proteins are
normalized to GAPDH. Pax7, Acetylated
protein, and GCN5 were significantly upregulated compared to control muscles. *
control vs. experimental = p < 0.05 ; **
control vs. experimental = p < 0.01.

Appendix Figure 2: 7 Day Recovery Protein Abundance
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Appendix Figure 3: 14 Day Recovery
Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots show Sirt1,
Pax7, Acetylation, GCN5, Sirt6, and
GAPDH proteins. B.) The relative
expression of protein data from the Western
Blots are summarized in the histograms at
the bottom of the figure for the control and
experimental muscles. The proteins are
normalized to GAPDH. All proteins were
significantly up-regulated compared to
control muscles. ** control vs. experimental
= p < 0.01.

Appendix Figure 3: 14 Day Recovery Protein Abundance

Appendix Figure 4: 21 Day Recovery
Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots show Sirt1,
Pax7, Acetylation, GCN5, Sirt6, and
GAPDH proteins. B.) The relative
expression of protein data from the Western
Blots are summarized in the histograms at
the bottom of the figure for the control and
experimental muscles. The proteins are
normalized to GAPDH. No proteins were
significantly different compared to control
muscles.

Appendix Figure 4: 21 Day Recovery Protein Abundance
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Figure 5: Sirt6 Protein Abundance.
A.) Representative Western Blot images are
shown for experimental (Ex.) injured
muscles that were injected with CTX and
the contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown 4,
7, 14, and 21 days after the respective
injections. B.) The relative expression of
Sirt6 data from the Western Blots are
summarized in the histograms at the bottom
of the figure for the control and
experimental muscles at each time point.
Sirt6 was normalized to GAPDH. Sirt6
expression was not significantly different
compared to control muscles at any time
point.

Appendix Figure 5: Sirt6 Protein Abundance

Figure 6: Pax7 Immunoprecipitation.
Representative Western Blot images from
the Pax7 pull-down and probed for Sirt1,
Acetylation, and GCN5 are shown for
experimental (Ex.) injured muscles that
were injected with CTX, and the
contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown
for the 4 day recovery.

Appendix Figure 6: 4 Day Recovery Pax7 Protein Interaction

Figure 7: Pax7 Immunoprecipitation.
Representative Western Blot images from
the Pax7 pull-down and probed for Sirt1,
Acetylation, and GCN5 are shown for
experimental (Ex.) injured muscles that
were injected with CTX, and the
contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown
for the 7 day recovery.
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Appendix Figure 7: 7 Day Recovery Pax7 Protein Interaction

Figure 8: Pax7 Immunoprecipitation.
Representative Western Blot images from
the Pax7 pull-down and probed for Sirt1,
Acetylation, and GCN5 are shown for
experimental (Ex.) injured muscles that
were injected with CTX, and the
contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown
for the 14 day recovery.

Appendix Figure 8: 14 Day Recovery Pax7 Protein Interaction

Figure 9: Pax7 Immunoprecipitation.
Representative Western Blot images from
the Pax7 pull-down and probed for Sirt1,
Acetylation, and GCN5 are shown for
experimental (Ex.) injured muscles that
were injected with CTX, and the
contralateral control (Ctrl.) muscles that
were injected with PBS. Blots are shown
for the 21 day recovery.

Appendix Figure 9: 21 Day Recovery Pax7 Protein Interaction

Mouse Morphometrics

Mouse
Set #1

Mouse
Set #2

Mouse
Set #3

Mouse
ID#

DOB

Sex

Recovery
Time

Injection
Date

Sacrifice
Date

Initial
Weight

Final
Weight

Left TA
Weight

Right TA
Weight

18

10/26/2013

M

4 Day

1/9/2014

1/13/2014

37.0g

33.7g

57.8mg

41.8mg

19

10/26/2013

M

4 Day

1/9/2014

1/13/2014

31.1g

30.4g

58.6mg

48.5mg

20

10/26/2013

M

4 Day

1/9/2014

1/13/2014

30.7g

29.0g

52.3mg

44.5mg

21

10/26/2013

M

4 Day

1/13/2014

1/17/2014

31.8g

30.3g

58.2mg

44.1mg

22

10/26/2013

M

4 Day

1/13/2014

1/17/2014

33.0g

31.5g

56.9mg

49.1mg

23

10/26/2013

M

4 Day

1/13/2014

1/17/2014

32.3g

31.0g

65.0mg

50.3mg

36

9/9/2013

M

7 Day

2/17/2014

2/24/2014

26.0g

27.0g

62.2mg

50.2mg

37

9/9/2013

M

7 Day

2/17/2014

2/24/2014

26.3g

26.7g

46.2mg

41.6mg

114

10/13/2013

F

7 Day

2/17/2014

2/24/2014

18.9g

19.4g

42.3mg

36.7mg
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Mouse
Set #4

Mouse
Set #5

117

10/13/2013

F

14 Day

3/17/2014

3/31/2014

21.5g

23.3g

49.3mg

40.4mg

118

10/13/2013

M

14 Day

3/17/2014

3/31/2014

33.9g

33.6g

58.1mg

51.0mg

119

10/13/2013

M

14 Day

3/17/2014

3/31/2014

28.5g

28.4g

53.5mg

52.7mg

113

10/13/2013

F

21 Day

2/17/2014

3/10/2014

18.5g

20.8g

43.7mg

55.3mg

115

10/13/2013

F

21 Day

2/17/2014

3/10/2014

22.2g

23.5g

49.4mg

53.0mg

116

10/13/2013

F

21 Day

2/17/2014

3/10/2014

20.9g

21.4g

47.1mg

49.3mg

Appendix Table 1: Mouse Morphometrics

Appendix B: Protocols & Solutions
Homogenization Protocol
Solutions & Materials
1.) Homogenization Buffer (*per 1mL of LB)
2.) 70% Ethanol
3.) ddH2O

10µL of Protease Inhibitor Cocktail
10µL of Phosphotase Inhibitor Cocktail II & III
10µL of NaVO3
10µL of PMSF
1µL of 1M DTT

Procedure
1.) Finely dice & mince muscle samples with razorblade on ice
2.) Add to 2mL homogenization tube with 300µL of homogenization buffer
3.) Homogenize sample (drill press w/ ceramic tip) 30-50x or until complete
4.) Remove homogenate & place in 1.5mL centrifuge tube on ice
5.) Clean ceramic tip & homogenization tube with 70% ethanol (3-5x) & ddH2O (5-7x) before homogenizing next sample
6.) Repeat for all muscle samples
7.) Centrifuge all samples @ 10,000rpm for 10min at 4°C
8.) Collect supernate & place in new 1.5mL centrifuge tube
a. Discard pellet
9.) Perform protein assay

Coomassie Protein Assay
Solutions & Materials
1.) Protein Standards (0µg/µL – 2,000µg/µL)
a. Diluted in ddH2O
2.) Protein homogenate
3.) 96-well plate
Procedure
1.) Add 5µL of protein standards & protein homogenate to wells
a. Need duplicates
2.) Add 250µL of Coomassie Blue to the wells
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3.) Run through machine

Preparing Loading Samples for Western Blot Analysis
Solutions & Materials
1.) Protein homogenate
2.) Lysis buffer
3.) 1M DTT
4.) 4x loading dye

1x Stock Cell Lysis Buffer (250mL)

226.25mL of ddH2O
12.5g of 1M Tris-HCl
7.5g of NaCl
0.525g of NaF
1.25mL of NP-40

Procedure
1.) Obtain data from Coomassie Protein Assay
a. 50-75µg/µL
2.) Add appropriate amounts of samples & solutions for 150µL of loading sample into 1.5mL centrifuge tube & vortex
a. XµL of sample, XµL of LB, 37.5µL of 4x loading dye, 7µL of 1M DTT
3.) Heat in the oven for 10min @ 70°C
4.) Cool to room temperature or store in -20°C

Western Blot Protocol
Solutions & Materials
 1x MES SDS Running Buffer (1L)
o Always make fresh
 1x TG Transfer Buffer (1L)
o Can be stored in 4°C
 Loading Samples
 Protein Ladder
o Novex Sharp Pre-stained Protein Ladder
 Antioxidant
 Ponceau Stain
 2% Blocking Buffer
 TBST
 4-12% Bis-Tris Premade Gel
 Nitrocellulose membrane
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4 Filter papers
4 Sponges
Blot Module
o Running & Transfer
1x MES SDS Running Buffer (1L)

1x Transfer Buffer (1L)

2% Blocking Solution (50mL)

1x TBST (1L)

950mL of ddH2O
50mL of 20x MES SDS Stock Running Buffer
750mL of ddH2O
200mL of Methanol
50mL of 20x TG Stock Transfer Buffer
50mL of TBST
1g of Smoke
900mL of ddH2O
100mL of 10x TBS
500µL of Tween 20

Procedure – Day 1
 Set up blot module with 1x MES SDS Running Buffer
 Wash wells of 4-12% Bis-Tris Gel with the running buffer
o Must remove comb & bottom sticker
 Fill blot module with running buffer so that the gel cassette is completely covered
 Lock cassette inside blot module
 Add 12-15µL of protein ladder in well(s)
 Add 30µL of loading samples into wells
 Run gel a@ 200V until protein runs completely through gel
o Set timer for 2.5hours
o *Prep Steps*
o *Pre-soak 4 sponges, 4 filter papers, & the nitrocellulose membrane in transfer buffer & store in
4°C until needed*
 Remove cassette & crack it open face down
 Carefully cut wells off of the top & apply 2 filter papers to back of gel
 Turn cassette over so that the filter papers are in your hand & push gel through followed by cutting off bottom gel strip
 Place gel & filter paper in a box filled with pre-cooled transfer buffer & place membrane on top
 Add 2 more filter papers on top of membrane & smooth so that there are no bubbles
 Remove filter paper/membrane combo & sandwich between the pre-soaked sponges inside the
transfer module
 Fill center of transfer module with transfer buffer so that it is thoroughly soaked by locking &
unlocking the blot lock
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 Fill outer compartment with pre-chilled (4°C) ddH2O & add 500µL of antioxidant to center
compartment
 Transfer in ice or 4°C cold room for 2:20hr @ 170mA
o * Prep Steps*
o *Make 50mL of 2% Blocking Solution & allow to stir for at least 30min*
 Remove membrane from module & stain with Ponceau Stain for 10-15min
 Wash non-specific Poneceau Stain with ddH2O & cut membrane for appropriate proteins
 Wash 3x5min in TBST
o Not including an initial wash & toss
 Block membrane strips in 2% Blocking Solution for 1hour
 Separate membrane strips & utilize blocking solution to create 1° antibodies
o Usually 1:1000 other than GAPDH (1:2000 or 1:5000 depending on strength)
 Rock membranes & 1° antibodies overnight at 4°C
Procedure – Day 2
 *Prepare 2° antibodies
o 1:1000 dilution in 2% Blocking Solution
 Collect 1° antibodies & store in -20°C
o Use no more than 5x
 Wash membrane strips 3x5min in TBST
o Not including an initial wash & toss
 Incubate membrane strips in 2° antibody on a rocker for 1hour
 Collect 2° antibodies & store in -20°C
o Use no more than 5x
 Wash membrane strips 4x15min in TBST
o Not including an initial wash & toss
o *Prep steps*
o *Create appropriate ECL solutions (Pico, Dura, & Femto) in a 1:1 ratio
 Dab membrane strips free of TBST & process in the dark with the ECL
o Pico: 3-5min
o Dura: 2.5min
o Femto: 2.5min
 Dab membrane strips free of ECL & place in cover sheet inside x-ray cassette & take to imager
 If necessary, re-probe with ECL
o Will need to was 3x3min in TBST prior to re-probing
 Save membrane strips in TBST if necessary

Immunoprecipitation Protocol
Solutions & Materials
 Protein homogenate
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Protein A & G magnetic beads
Magnetic separator
Tube rotator
1x Stock lysis buffer
IP wash buffer
ddH2O
Antibodies
IP 1x elution buffer

1x Stock Cell Lysis Buffer (250mL)

IP Wash Buffer (50mL)

IP 1x Elution Buffer (30µL)

226.25mL of ddH2O
12.5g of 1M Tris-HCl
7.5g of NaCl
0.525g of NaF
1.25mL of NP-40
50mL of TBST
1.46g of NaCl
21µL of LB
8µL of 4x Loading Dye
2.8µL of 10x Reducing Agent

Procedure – Day 1
 Use 150-200µg/µL protein homogenate per sample
o Obtained from Coomassie protein assay
 Separate 25µL of magnetic protein A/G beads in magnetic separator & discard supernate
o No vortexing; finger flick only to avoid bead damage
 Add the protein homogenate to beads & rotate @ 4°C for 1hour to pre-clean the protein
 *Prep-step*
 * Obtain new 1.5mL tubes for corresponding samples & bring total volume (including current
pre-cleaning protein) to 500µL with 1x lysis buffer & 10µL of pull-down antibody*
 Separate protein from beads in the magnetic separator & add supernate to the prep-step tubes
o Antigen + antibody = new tubes
o Discard the tubes with the beads
 Rotate antigen & antibody mixture @ 4°C for 2hours
 *Prep-step*
 *Pre-clean 25µL of new protein A/G beads for each sample with IP wash buffer*
o 1st wash - 200µL for 3min
o 2nd wash - 500µL for 3min
o 3rd wash - 500µL for 3min
 Combine antigen & antibody with new pre-cleaned magnetic A/G beads & rotate @ 4°C overnight
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Procedure – Day 2
 *Prep-step*
 *Turn oven on to 70°C*
 Collect beads with magnetic separator & discard the supernate
 Wash beads with 500µL of IP wash buffer 3x1.5min
 Wash beads with 500µL of ddH2O for 1.5min
 Add 30µL of IP 1x elution buffer to each sample
 Heat samples @ 70°C for 10min
o Only if Ø rabbit antibody
 Remove beads & save supernate
 Allow to cool to room temperature or store @ -20°C
 Run as a normal Western Blot

Membrane Stripping Protocol
Solutions & Materials
 Membrane strips
 Oven w/ rotator
 Stripping Buffer
 1x TBST
 2% Blocking Solution

Stripping Buffer (100mL)

2% Blocking Solution (50mL)

1x TBST (1L)

100mL ddH2O
0.699mL of 100mM 2-Mercaptoethanol
2g of 2% SDS
0.985g of Tris-HCl
50mL of TBST
1g of Smoke
900mL of ddH2O
100mL of 10x TBS
500µL of Tween 20

Procedure:
 *Prep-Steps*
o Make appropriate amount of 2% Blocking Solution & allow to stir for 30min
o Pre-warm 50mL of Stripping Buffer in the oven @ 55°C for 30min with rotation
 Place all membranes in Stripping Buffer & rotate @ 55°C for 10min
 Remove membrane strips & wash 3x5min in 1x TBST
o Can reuse Stripping buffer 5x
 Block membrane strips for 30min in 2% Blocking Solution
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Add primary antibodies & rock overnight @ 4°C
Continue with day 2 of Western Blot Protocol

Immunohistochemisrty Protocol
Solutions & Materials
 Tissue sections
 1x PBS
 IHC blocking buffer
 IHC formaldehyde fixing solution
 IHC antibody dilution buffer
 3 covered glass Coplin jars
 Pap-pen or wax pencil
1x PBS (1L)

IHC 4% Formaldehyde Fixing Solution (200mL)

IHC Blocking Buffer (10mL)

IHC Antibody Dilution Buffer (10mL)

900mL of ddH2O
100mL of 10x PBS
200mL of 1x PBS
8g of Paraformaldehyde
9mL of 1x PBS
500µL of Normal Serum (same animal as 2°)
30µL of Triton X-100 (last & while stirring)
10mL of 1x PBS
30µL of Triton X-100
0.1g of BSA (last)

Procedure – Day 1
 *Prep-step*
 *Make 200mL of IHC 4% formaldehyde fixing solution on warm hot plate while stirring*
 *Warm tissue sections to room temperature*
 Fix tissue sections (on slides) in paraformaldehyde-specific Coplin jar for 15min
 Wash slides 3x5min in 1x PBS
o Store IHC 4% formaldehyde fixing solution in 4°C
 Can store in 4°C for 1week
o Alternate between 2 Coplin jars with 1x PBS already inside to avoid washing off tissue
sections
 *Prep-step*
 *Make fresh IHC blocking buffer*
 Block slide for 1hour in IHC blocking buffer
o Make fresh every time – do not store
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 *Prep-step*
 *Make fresh IHC antibody dilution buffer*
 *Add primary antibody(s) to IHC antibody dilution buffer*
o Can store IHC dilution buffer in 4°C for 1week
 Remove blocking solution carefully with kimwipe & place slides flat on soaked sponge in box
with H2O to keep slides hydrated
o Do not touch tissue sections with kimwipe
 Ring sections with pap-pen or wax pencil & apply 50µL of 1° antibody(s)
 Incubate @ 4°C in dark box overnight with lid to prevent evaporation
Procedure – Day 2
 Wash slides 3x5min in 1x PBS
o Alternate Coplin jars to avoid washing off tissues
 *Prep-step*
 *Go to complete dark area – absolutely no light*
 *Make fresh IHC antibody dilution buffer with fluorochrome-conjugated 2° antibody*
 Remove excess 1x PBS from slides & place in dark & covered box with soaked sponges with
H2O in bottom
o Make sure the slides are level
 Incubate slide in 50µL of 2° antibody for 1-2hours @ room temperature
 Rinse 3x5min in 1x PBS
 Remove excess 1x PBS with kimwipe
 Add 1 drop of DAPI to each tissue section & carefully add coverslip
 Incubate overnight & store in 4°C

Solution

Components

1x TBST (1L)

900mL of ddH2O
100mL of 10x TBS
500µL of Tween 20

1x PBS (1L)

900mL of ddH2O
100mL of 10x PBS

1x MES SDS Running Buffer (1L)

1x Transfer Buffer (1L)

1x Stock Cell Lysis Buffer (250mL)

950mL of ddH2O
50mL of 20x MES SDS Stock Running Buffer
750mL of ddH2O
200mL of Methanol
50mL of 20x TG Stock Transfer Buffer
226.25mL of ddH2O
12.5g of 1M Tris-HCl
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7.5g of NaCl
0.525g of NaF
1.25mL of NP-40

Homogenization Buffer (*All are per 1mL LB*)

2% Blocking Solution (50mL)

Stripping Buffer (100mL)

IP 1x Elution Buffer (30µL)

IP Wash Buffer (50mL)

10µL of Protease Inhibitor Cocktail
10µL of Phosphotase Inhibitor Cocktail II & III
10µL of NaVO3
10µL of PMSF
1µL of 1M DTT
50mL of TBST
1g of Advanced ECL Blocking Reagent
100mL ddH2O
0.699mL of 100mM 2-Mercaptoethanol
2g of 2% SDS
0.985g of Tris-HCl
21µL of LB
8µL of 4x Loading Dye
2.8µL of 10x Reducing Agent
50mL of TBST
1.46g of NaCl

Cell Culture Digestion Solution I (18mL)

16.2mL of F10
1.8mL of Heart Serum
26.82mg of Collagenase II

Cell Culture Digestion Solution II (18mL)

16.2mL of F10
1.8mL of Heart Serum
5.4mg of Collagenase II
18U of Dispase II

IHC Blocking Buffer (10mL)

IHC Antibody Dilution Buffer (10mL)

IHC 4% Formaldehyde Fixing Solution (200mL)

9mL of 1x PBS
500µL of Normal Serum (same animal as 2°)
30µL of Triton X-100 (last & while stirring)
10mL of 1x PBS
30µL of Triton X-100
0.1g of BSA (last)
160mL or 200mL of 1x PBS
40mL of Formaldehyde or 8g of Paraformaldehyde
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